Company profile
908 Devices Inc.
NASDAQ: MASS · Healthcare · Medical - Specialties
#417 of 1,418 Healthcare companies by revenue35th-percentile growth
EA Score
60CFH 72DQ 46GM 53SS 57
v0.1 · 65/100 weight · provisional
↑ net margin, return on assets · ↓ Piotroski F, listing tenure
Methodology →Revenue TTM
$57.8M
Rev growth YoY (TTM)
+2.2%
Net income (FY)
$19.5M
Employees
172
as of 2026-08-12
Market cap
$410.7M
as of 2026-08-12
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$56.2M$56.2M2025
Net income$19.5M$19.5M2025
Operating income-$39.4M-$39.4M2025
Total assets$190.1M$190.1M2025
Liabilities$46.4M$46.4M2025
Equity$143.7M$143.7M2025
Revenue trend
FY2021 – FY2025 · USD
FY21
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Device Sales58%
Recurring31%
Product and service revenue11%
Contract0%
By geography
UNITED STATES73%
Europe, Middle East and Africa19%
Asia Pacific5%
Americas other3%
The read
What is 908 Devices Inc.’s revenue?
908 Devices Inc. booked $56.2M in FY2025 revenue, contracting 5.8% year over year — slower than 65% of Healthcare companies we track, at a 34.7% net margin.
Peers · Healthcare
Champions Oncology, Inc.——CVRx, Inc.50DHLS Therapeutics Inc.64CNektar Therapeutics50DThe Joint Corp.75B+Integrated BioPharma, Inc.67BNeighbors
Middlesex →Key facts
CEOKevin J. Knopp
SectorHealthcare
IndustryMedical - Specialties
HeadquartersBurlington, MA
ExchangeNASDAQ: MASS
Employees172
IPO date2020-12-18
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.